

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8041319

| | | |
|---|---|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | ASSIGNMENT | |
| CONVEYING PARTY DATA | | |
| | Name | Execution Date |
| | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 10/30/2020 |
| RECEIVING PARTY DATA | | |
| Name: | XYNOMIC PHARMACEUTICALS, INC. | |
| Street Address: | 3500 SOUTH DUPONT HIGHWAY, SUITE SS101 | |
| City: | DOVER | |
| State/Country: | DELAWARE | |
| Postal Code: | 19901 | |
| PROPERTY NUMBERS Total: 1 | | |
| | Property Type | Number |
| | Application Number: | 17692695 |
| CORRESPONDENCE DATA | | |
| Fax Number: | (877)769-7945 | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | |
| Phone: | 6508395070 | |
| Email: | apsi@fr.com | |
| Correspondent Name: | FISH & RICHARDSON P.C. | |
| Address Line 1: | P.O. BOX 1022 | |
| Address Line 4: | MINNEAPOLIS, MINNESOTA 55402-1022 | |
| ATTORNEY DOCKET NUMBER: | 44779-0004002 | |
| NAME OF SUBMITTER: | CRENA PACHECO | |
| SIGNATURE: | /CRENA PACHECO/ | |
| DATE SIGNED: | 07/05/2023 | |
| Total Attachments: 6 | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page1.tif | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page2.tif | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page3.tif | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page4.tif | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page5.tif | | |
| source=Assignment BI International to Xynomic Pharmaceuticals, Inc#page6.tif | | |

ASSIGNMENT

Assignor: Boehringer Ingelheim International GmbH
a Corporation organized and existing under the laws of Germany, and having a place
of business at:
Binger Strasse 173
Ingelheim am Rhein, Germany 55216

Assignee: Xynomic Pharmaceuticals, Inc.
a Corporation organized and existing under the laws of
Wyoming, and having a place of business at:
3500 South DuPont Highway, Suite 55101
Dover, DE 19901

| Country | Application No. | Filing Date | Title |
|---------------|-------------------|------------------|---|
| United States | 62/577,313 | October 26, 2017 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| United States | 16/759,187 | April 24, 2020 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| WIPO | PCT/US2018/057792 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Australia | 2018355528 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Brazil | BR112020008248-1 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Canada | 3080324 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| China | 201880081003.9 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Europe | 18801183.7 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |

| | | | |
|-------------|------------------|------------------|---|
| Indonesia | P00202003739 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Israel | 274027 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| India | 202017021378 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Japan | 2020-543248 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| South Korea | 10-2020-7014962 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Mexico | MX/a/2020/004148 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Malaysia | PI2020001994 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| New Zealand | 763794 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Philippines | 1-2020-550485 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Russia | 2020116763 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Singapore | 11202003635T | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Thailand | 2001002292 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |
| Vietnam | 1-2020-02933 | October 26, 2018 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR |

- Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority

- from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.
 3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
 4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
 5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.

Attorney Docket Nos. 44779-0004P01 & 44779-0004WO1
Assignment from Boehringer Ingelheim International GmbH to Xynomic Pharmaceuticals, Inc.

6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

TH
As
Di
BC
PP
C
Dr

The Assignor hereby executes this Assignment.

Assignor: Boehringer Ingelheim International GmbH

Date: October 30, 2020

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

ppa.




Dr. Elke SIMON



Dr. Markus WEYMANN

Managing Directors

Certificate verifying signature



I hereby certify the above signatures of

Dr. Elke Simon,

born 09th day of June 1961,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

Dr. Markus Weymann,

born 27th day of December 1966,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,


personally known,

were duly given in my presence.

Ingelheim am Rhein, the 30th day of October 2020

Prof. Dr. Keim

notary public



PATENT